SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, will announce financial results for its second quarter ended June 30, 2008, on Thursday, August 7, 2008, after the markets close. The announcement will be followed by a live webcast and conference call at 2:00 p.m. Pacific Time.
Orexigen management will host the call and webcast to discuss results for the second quarter ended June 30, 2008, and recent business highlights. The live call may be accessed by phone by calling (800) 860-2442 (domestic) or (412) 858-4600 (international). The webcast can be accessed live on the investor relations section of the Company's Web site at http://www.orexigen.com and will be archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on
the development of pharmaceutical product candidates for the treatment of
central nervous system disorders, including obesity. The Company's lead
combination product candidates targeted for obesity are Contrave(R), which
is in Phase III clinical trials, and Empatic(TM), which is in the later
stages of Phase II clinical development. Both product candidates take
advantage of the Company's understanding of how the brain appears to
regulate appetite and energy expenditure, as well as the mechanisms that
come into play to limit weight loss over time. Each product candidate is
designed to act on a specific group of neurons in the central nervous
system with the goal of achieving appetite suppression and sustained weight
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved